Therapeutics(34)
-
Bispecific Immune Synapse Engagers as Immunotherapy for Oncology and Autoimmunity (No. T4-2176)
Dysfunctional immune circuits underlie many diseases, including cancer and autoimmunity. Current immunotherapies often target a single pathway or cell type, limiting their efficacy. ... Read more19180 -
Novel Antibody Therapeutics Targeting Senescent Cells for Cancer and Fibrotic Disease Treatment (No. T4-2158)
Senescent cells play a dual role in cancer and fibrosis, where their persistent presence can drive chronic inflammation, tissue remodeling, and disease progression. ... Read more19186 -
MMP14 targeting natural antibodies to treat ovarian cancer (No. T4-2152)
MMP14 is a major antibody target on the tumor cell surface as it is highly expressed on tumor cells and plays a key role in cancer progression and metastasis. Natural occurring autoantibodies targeting MMP14 were isolated from ovarian cancer patients. ... Read more17825 -
Novel Combination Therapy For Improved Management of Depression (No. T4-2129)
A novel combination therapy pairing ketamine with retigabine, an FDA-approved KCNQ channel activator, offers a promising strategy for mood-related disorders. ... Read more6097 -
Modulating Weight Gain and Loss by Understanding the Mechanism of Smoking Related Weight Changes (No. T4-2078)
A new approach to prevent weight gain during smoking cessation (SCWG) focuses on the gut microbiome and metabolites like dimethylglycine (DMG) and acetylglycine (ACG). ... Read more17357 -
Biosynthetic pathways for producing Psychedelics (No. T4-2077)
Applying a multitude of enzymes to generate biosynthetic pathways to synthesize different Psychedelics such as DMT, Psilocin, Psilocybin, Peyote related compounds, and so on. ... Read more19433 -
Enhanced Anti-PD-L1 Immunotherapy (No. T4-2059)
A novel approach for enhancing the efficacy of PD-L1 targeting antibodies by harnessing beneficial FcγR signaling pathways. Strategy involves either (1) Co-administration of PD-L1 targeting antibodies with an FcγRIIB-blocking antibody or ... Read more17039 -
APP–Tau bispecific peptide inhibitor for the treatment of Alzheimer’s Disease (No. T4-2057)
The interaction between APP and Tau, two central drivers of Alzheimer’s pathology, is increasingly recognized as a critical factor in disease progression. ... Read more
Ruth Arnon
Faculty of Biology6160 -
Covalent Chemistry Platform for Diagnostics and Drug Discovery (No. T4-2045)
CoLDR (Covalent Ligand-Directed Release) chemistry enables site-specific covalent labeling and activation of endogenous proteins using small-molecule covalent ligands. ... Read more6106 -
Safer CAR-T Cell Platform (No. T4-2033)
A platform for engineering CAR-T cells with enhanced cancer-killing ability and reduced toxicity. By redesigning the transmembrane domain of the CAR using a computational protein design platform, researchers created synthetic receptors that form stable, specific oligomeric structures. ... Read more6124
Pages
